ArticleEuropean journal of histochemistry : EJH2021
Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters.
Article in European journal of histochemistry : EJH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Siglec-15 Expression in Gastric Carcinoma and Its Association With Clinicopathological Variables.World journal of oncology · 2026Article
- Sialic acid-modified phosphorene for low-necrosis and targeted drug delivery in breast cancer.RSC advances · 2026Article
- Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric Cancer.International journal of molecular sciences · 2025Article
- Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer.Histology and histopathology · 2025Article
- Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer.International journal of molecular sciences · 2025Review
- Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.Journal of hematology & oncology · 2024Article
- The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma.The clinical respiratory journal · 2024Article
- Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.BMC cancer · 2024Article
- Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma.Heliyon · 2024Article
- Siglec15 in blood system diseases: from bench to bedside.Frontiers in immunology · 2024Review
- Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.Frontiers in oncology · 2024Article
- SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.Oncoimmunology · 2024Article
- Significance of Siglec-15 expression in colorectal cancer: association with advanced disease stage and fewer tumor-infiltrating lymphocytes.The journal of pathology. Clinical research · 2023Article
- Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma.Journal of Cancer · 2023Article
- Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.The journal of pathology. Clinical research · 2022Article
- Unveiling the molecular features, relevant immune and clinical characteristics ofFrontiers in immunology · 2022Article
- Exploration of the Tumor Immune Landscape and Identification of Two Novel Immunotherapy-Related Genes for Epstein-Barr virus-associated Gastric CarcinomaFrontiers in surgery · 2022Article
- Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sialic acid-binding immunoglobulin-type lectin Siglec-15 is a promising target to cancer immunotherapy in several tumor types. The present study aimed to investigate Siglec-15 expression in gastric cancer (GC) patient tissue and to evaluate its clinical value. Siglec-15 expression was evaluated by immunohistochemistry with 71 patients. Siglec-15 staining was observed in tumor cells of 53 (74.64%) patients, with significant association with histologic classification and angiolymphatic invasion (p<0.05). Immunohistochemistry analysis also detected Siglec-15 in tumor-associated stroma cells (macrophages/myeloid cells). There was no significant association with outcomes parameters. Siglec-15 expression in well differentiated histological GC tissues and in the tumor microenvironment are potential targets to be further investigated as a novel prognostic factor for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.